Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReVenG: Venetoclax-Obinutuzumab Retreatment in CLL
NCT04895436Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of venetoclax in chronic lymphocytic leukemia (CLL), sponsored by AbbVie Inc.. Started Mar 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04895436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895436.